Shattuck Labs, Inc. (STTK) stock
Close on Nov 11, 2026Market cap $506.83MP/E –Yield –
Shattuck Labs, Inc. saw revenue fall 100.0% to $0 over the twelve months to Sep 30, 2026. Free cash flow was -$39.95M. At the latest close the market valued the company at $506.83M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $506.83M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.62
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$67.72M
- EPS, diluted
- -$0.51
- Free cash flow
- -$39.95M
- Book value per share
- $0.00
- Diluted shares
- 183.22B
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $4.85
- Open
- $4.89
- Day's range
- $4.86 – $5.09
- Volume
- 984,476
- Average volume (20 days)
- 942,015
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.64
- 52-week range
- $1.72 – $8.33
- RSI (14 days)
- 42.6
- Volatility (1 year)
- 78.2%
- Relative volume
- 0.85×
- WACC
- 13.1%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | STTK | S&P 500 | Difference | STTK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.4% | -2.4% | −13.0 pts | ||
| 3 months | -29.7% | -1.2% | −28.5 pts | ||
| Year to date | +38.4% | +12.3% | +26.1 pts | ||
| 1 year | +155.1% | +12.4% | +142.6 pts | ||
| 3 years | +174.5% | +78.8% | +95.6 pts | +40.0% | +21.4% |
| 5 years | -61.5% | +75.2% | −136.6 pts | -17.4% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Shattuck Labs filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
About Shattuck Labs
Pharmaceutical Preparations
The company is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. It specializes in protein engineering to discover and advance monoclonal and bispecific antibodies that target the Death Receptor 3 (DR3) pathway. Its lead investigational product candidate is SL-325, a DR3-blocking monoclonal antibody intended to treat conditions such as inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. In addition, the pipeline includes SL-425, an extended half-life version of its primary candidate, alongside multiple preclinical bispecific antibodies designed to simultaneously inhibit DR3 and other biologically relevant disease pathways.
Company profile, executives and historyShattuck Labs stock: common questions
What is Shattuck Labs's stock price?
STTK closed at $5.05 on Nov 11, 2026, up 4.12% on the day. Over the past 52 weeks it traded between $1.72 and $8.33.
What is Shattuck Labs's market cap?
Shattuck Labs was worth $506.83M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is STTK's P/E ratio?
Shattuck Labs lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.51), so it has no meaningful P/E ratio.
How much revenue does Shattuck Labs make?
Shattuck Labs reported revenue of $0 for the twelve months to Sep 30, 2026, down 100.0% from a year earlier.
Does Shattuck Labs pay a dividend?
No. Shattuck Labs has not paid a cash dividend over the last twelve months.
When does Shattuck Labs report earnings next?
Shattuck Labs is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has STTK stock performed over the past year?
Including dividends, STTK returned +155.1% over the past year, against +12.4% for the S&P 500.
How many STTK shares are sold short?
11M shares were sold short at the latest FINRA report, 14.11% of the float, or 12.0 days of average trading volume.
Who are Shattuck Labs's competitors?
Companies most similar to Shattuck Labs by business, industry and size include IBIO, YARW, DNTH, RNAC, MCRB.
See a number that looks wrong?